Viatris Inc. (VTRS) Stock

Viatris Inc. operates as a global healthcare company, providing a wide range of medical products and services. The company is structured into four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers a diverse portfolio of prescription brand drugs, generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs). Viatris addresses various therapeutic areas, including noncommunicable and infectious diseases, and offers biosimilars in oncology, immunology, endocrinology, ophthalmology, and dermatology. Additionally, the company provides APIs for treatments involving antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors, along with support services like diagnostic clinics, educational seminars, and digital tools to enhance patient health management.

Viatris delivers its medications in multiple forms, including oral solid doses, injectables, complex dosage forms, and APIs, catering to a broad spectrum of retail and pharmacy establishments, wholesalers and distributors, payers, insurers, governments, and institutions. The company's distribution network includes pharmaceutical wholesalers, retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. Notable product names under Viatris' extensive portfolio include Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri, among others. The company also offers biosimilar franchises such as Fulphila, Ogivri, Hulio, and SEMGLEE.

In addition to its robust product offerings, Viatris has entered into collaboration and licensing agreements with several key partners, including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961 and headquartered in Canonsburg, Pennsylvania, Viatris is committed to providing high-quality healthcare solutions and improving patient outcomes worldwide.